Does aspirin consumption affect the presentation or severity of acute myocardial infarction?

N. F. Col, J. Yarzebski, J. M. Gore, Joseph S Alpert, R. J. Goldberg

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: While consumption of aspirin has been shown to decrease the occurrence of nonfatal cardiac events, the majority of studies have not demonstrated any impact of aspirin intake on cardiovascular mortality. The present population-based study explores the possibility that aspirin consumption affects the presentation and severity of acute myocardial infarction (AMI), and hence the likelihood of clinical detection. Methods: We monitored the use of aspirin before admission for 2114 patients with a validated diagnosis of AMI in 16 hospitals in the Worcester, Mass, metropolitan area during 1986, 1988, and 1990. The AMIs were characterized as Q wave vs non-Q wave and large (peak creatine kinase levels more than five times normal) vs small (peak creatine kinase levels less than two tines normal). Results: A total of 332 patients (16%) with validated AMI took aspirin before hospital admission. Nearly, 65% of aspirin users had non-Q- wave AMIs, compared with 49% of nonaspirin users. Thirty percent of aspirin users sustained small AMIs, compared with 22% of nonaspirin users. These findings persisted after stratifying for previous AMI, history of coronary disease, receipt of thrombolytic therapy, and exclusion of early hospital deaths. Using multivariable regression models to control for age, gender, previous evidence of coronary disease, and use of other meditations, prior aspirin consumption remained independently associated with AMI type (non-Q- wave AMI) and smaller infarct size. Conclusion: Aspirin consumption appears to modify the presentation of AMI, increasing the likelihood that the infarct will be of the small, non-Q-wave variety.

Original languageEnglish (US)
Pages (from-to)1386-1389
Number of pages4
JournalArchives of Internal Medicine
Volume155
Issue number13
StatePublished - 1995

Fingerprint

Aspirin
Myocardial Infarction
Creatine Kinase
Coronary Disease
Meditation
Patient Admission
Thrombolytic Therapy
Mortality
Population

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Does aspirin consumption affect the presentation or severity of acute myocardial infarction? / Col, N. F.; Yarzebski, J.; Gore, J. M.; Alpert, Joseph S; Goldberg, R. J.

In: Archives of Internal Medicine, Vol. 155, No. 13, 1995, p. 1386-1389.

Research output: Contribution to journalArticle

Col, NF, Yarzebski, J, Gore, JM, Alpert, JS & Goldberg, RJ 1995, 'Does aspirin consumption affect the presentation or severity of acute myocardial infarction?', Archives of Internal Medicine, vol. 155, no. 13, pp. 1386-1389.
Col, N. F. ; Yarzebski, J. ; Gore, J. M. ; Alpert, Joseph S ; Goldberg, R. J. / Does aspirin consumption affect the presentation or severity of acute myocardial infarction?. In: Archives of Internal Medicine. 1995 ; Vol. 155, No. 13. pp. 1386-1389.
@article{2e787c9087aa4893aa1b91ab5d5cd094,
title = "Does aspirin consumption affect the presentation or severity of acute myocardial infarction?",
abstract = "Background: While consumption of aspirin has been shown to decrease the occurrence of nonfatal cardiac events, the majority of studies have not demonstrated any impact of aspirin intake on cardiovascular mortality. The present population-based study explores the possibility that aspirin consumption affects the presentation and severity of acute myocardial infarction (AMI), and hence the likelihood of clinical detection. Methods: We monitored the use of aspirin before admission for 2114 patients with a validated diagnosis of AMI in 16 hospitals in the Worcester, Mass, metropolitan area during 1986, 1988, and 1990. The AMIs were characterized as Q wave vs non-Q wave and large (peak creatine kinase levels more than five times normal) vs small (peak creatine kinase levels less than two tines normal). Results: A total of 332 patients (16{\%}) with validated AMI took aspirin before hospital admission. Nearly, 65{\%} of aspirin users had non-Q- wave AMIs, compared with 49{\%} of nonaspirin users. Thirty percent of aspirin users sustained small AMIs, compared with 22{\%} of nonaspirin users. These findings persisted after stratifying for previous AMI, history of coronary disease, receipt of thrombolytic therapy, and exclusion of early hospital deaths. Using multivariable regression models to control for age, gender, previous evidence of coronary disease, and use of other meditations, prior aspirin consumption remained independently associated with AMI type (non-Q- wave AMI) and smaller infarct size. Conclusion: Aspirin consumption appears to modify the presentation of AMI, increasing the likelihood that the infarct will be of the small, non-Q-wave variety.",
author = "Col, {N. F.} and J. Yarzebski and Gore, {J. M.} and Alpert, {Joseph S} and Goldberg, {R. J.}",
year = "1995",
language = "English (US)",
volume = "155",
pages = "1386--1389",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "13",

}

TY - JOUR

T1 - Does aspirin consumption affect the presentation or severity of acute myocardial infarction?

AU - Col, N. F.

AU - Yarzebski, J.

AU - Gore, J. M.

AU - Alpert, Joseph S

AU - Goldberg, R. J.

PY - 1995

Y1 - 1995

N2 - Background: While consumption of aspirin has been shown to decrease the occurrence of nonfatal cardiac events, the majority of studies have not demonstrated any impact of aspirin intake on cardiovascular mortality. The present population-based study explores the possibility that aspirin consumption affects the presentation and severity of acute myocardial infarction (AMI), and hence the likelihood of clinical detection. Methods: We monitored the use of aspirin before admission for 2114 patients with a validated diagnosis of AMI in 16 hospitals in the Worcester, Mass, metropolitan area during 1986, 1988, and 1990. The AMIs were characterized as Q wave vs non-Q wave and large (peak creatine kinase levels more than five times normal) vs small (peak creatine kinase levels less than two tines normal). Results: A total of 332 patients (16%) with validated AMI took aspirin before hospital admission. Nearly, 65% of aspirin users had non-Q- wave AMIs, compared with 49% of nonaspirin users. Thirty percent of aspirin users sustained small AMIs, compared with 22% of nonaspirin users. These findings persisted after stratifying for previous AMI, history of coronary disease, receipt of thrombolytic therapy, and exclusion of early hospital deaths. Using multivariable regression models to control for age, gender, previous evidence of coronary disease, and use of other meditations, prior aspirin consumption remained independently associated with AMI type (non-Q- wave AMI) and smaller infarct size. Conclusion: Aspirin consumption appears to modify the presentation of AMI, increasing the likelihood that the infarct will be of the small, non-Q-wave variety.

AB - Background: While consumption of aspirin has been shown to decrease the occurrence of nonfatal cardiac events, the majority of studies have not demonstrated any impact of aspirin intake on cardiovascular mortality. The present population-based study explores the possibility that aspirin consumption affects the presentation and severity of acute myocardial infarction (AMI), and hence the likelihood of clinical detection. Methods: We monitored the use of aspirin before admission for 2114 patients with a validated diagnosis of AMI in 16 hospitals in the Worcester, Mass, metropolitan area during 1986, 1988, and 1990. The AMIs were characterized as Q wave vs non-Q wave and large (peak creatine kinase levels more than five times normal) vs small (peak creatine kinase levels less than two tines normal). Results: A total of 332 patients (16%) with validated AMI took aspirin before hospital admission. Nearly, 65% of aspirin users had non-Q- wave AMIs, compared with 49% of nonaspirin users. Thirty percent of aspirin users sustained small AMIs, compared with 22% of nonaspirin users. These findings persisted after stratifying for previous AMI, history of coronary disease, receipt of thrombolytic therapy, and exclusion of early hospital deaths. Using multivariable regression models to control for age, gender, previous evidence of coronary disease, and use of other meditations, prior aspirin consumption remained independently associated with AMI type (non-Q- wave AMI) and smaller infarct size. Conclusion: Aspirin consumption appears to modify the presentation of AMI, increasing the likelihood that the infarct will be of the small, non-Q-wave variety.

UR - http://www.scopus.com/inward/record.url?scp=0029061719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029061719&partnerID=8YFLogxK

M3 - Article

C2 - 7794087

AN - SCOPUS:0029061719

VL - 155

SP - 1386

EP - 1389

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 13

ER -